Literature DB >> 16385110

Phenotypic switching in Cryptococcus neoformans.

A Guerrero1, N Jain2, D L Goldman3, B C Fries4.   

Abstract

Phenotypic switching has been described in serotype A and D strains of Cryptococcus neoformans. It occurs in vivo during chronic infection and is associated with differential gene expression and changes in virulence. The switch involves changes in the polysaccharide capsule and cell wall that affect the yeast's ability to resist phagocytosis. In addition, the phenotypic switch variants elicit qualitatively different inflammatory responses in the host. In animal models of chronic cryptococosis, the immune response of the host ultimately determines which of the switch variants are selected and maintained. The importance of phenotypic switching is further underscored by several findings that are relevant in the setting of human disease. These include the ability of the mucoid colony variant of RC-2 (RC-2 MC) but not the smooth variant (RC-2 SM) to promote increased intracerebral pressure in a rat model of cryptococcal meningitis. Furthermore, chemotherapeutic and immunological antifungal interventions can promote the selection of the RC-2 MC variant during chronic murine infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16385110      PMCID: PMC2721797          DOI: 10.1099/mic.0.28451-0

Source DB:  PubMed          Journal:  Microbiology (Reading)        ISSN: 1350-0872            Impact factor:   2.777


  16 in total

1.  Regulation of Cryptococcus neoformans capsule size is mediated at the polymer level.

Authors:  Aki Yoneda; Tamara L Doering
Journal:  Eukaryot Cell       Date:  2007-12-21

2.  Neurovirulence of Cryptococcus neoformans determined by time course of capsule accumulation and total volume of capsule in the brain.

Authors:  A Pool; L Lowder; Y Wu; K Forrester; J Rumbaugh
Journal:  J Neurovirol       Date:  2013-06-04       Impact factor: 2.643

3.  New insights on the pathogenesis of invasive Cryptococcus neoformans infection.

Authors:  Helene C Eisenman; Arturo Casadevall; Erin E McClelland
Journal:  Curr Infect Dis Rep       Date:  2007-11       Impact factor: 3.725

4.  Characterization of phenotypic switching in Cryptococcus neoformans biofilms.

Authors:  Luis R Martinez; David C Ibom; Arturo Casadevall; Bettina C Fries
Journal:  Mycopathologia       Date:  2008-06-21       Impact factor: 2.574

5.  Cryptococcus neoformans responds to mannitol by increasing capsule size in vitro and in vivo.

Authors:  Allan Jefferson Guimarães; Susana Frases; Radamés J B Cordero; Leonardo Nimrichter; Arturo Casadevall; Joshua D Nosanchuk
Journal:  Cell Microbiol       Date:  2010-01-11       Impact factor: 3.715

6.  Incorporation of 2-amino-thiophene derivative in nanoparticles: enhancement of antifungal activity.

Authors:  Wendell Wons Neves; Rejane Pereira Neves; Danielle Patrícia Cerqueira Macêdo; Giovanna Rodrigues de Araújo Eleamen; Elisângela Afonso de Moura Kretzschmar; Elquio Eleamen Oliveira; Francisco Jaime Bezerra Mendonça-Junior; Reginaldo Gonçalves de Lima-Neto
Journal:  Braz J Microbiol       Date:  2020-03-05       Impact factor: 2.476

7.  Phenotypic Plasticity in the Productions of Virulence Factors Within and Among Serotypes in the Cryptococcus neoformans Species Complex.

Authors:  Yajur Iyengar; Jianping Xu
Journal:  Mycopathologia       Date:  2021-10-25       Impact factor: 2.574

8.  DNA mutations mediate microevolution between host-adapted forms of the pathogenic fungus Cryptococcus neoformans.

Authors:  Denise A Magditch; Tong-Bao Liu; Chaoyang Xue; Alexander Idnurm
Journal:  PLoS Pathog       Date:  2012-10-04       Impact factor: 6.823

Review 9.  Molecular mechanisms of cryptococcal meningitis.

Authors:  Tong-Bao Liu; David S Perlin; Chaoyang Xue
Journal:  Virulence       Date:  2012-03-01       Impact factor: 5.882

10.  Functional organisation of Escherichia coli transcriptional regulatory network.

Authors:  Agustino Martínez-Antonio; Sarath Chandra Janga; Denis Thieffry
Journal:  J Mol Biol       Date:  2008-05-29       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.